Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR BGB-290

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for BGB-290

Subscribe to access the full database, or Sign up for a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02343120 ↗	Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies	Completed	BeiGene	Phase 1/Phase 2	This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.
NCT02361723 ↗	Phase 1a/1b BGB-290 for Advanced Solid Tumors.	Completed	BeiGene	Phase 1	The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2 (QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one cycle of treatment at that dose level and dose regimen is required prior to determining the next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing Expansion) will investigate efficacy in participants with selected tumor types and further evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB (Food Effect) will investigate the food effect on the Pharmacokinetics (PK) of BGB 290 in participants with advanced solid tumors.
NCT02569476 ↗	BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies	Completed	BeiGene	Phase 1	This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
NCT02610361 ↗	Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors	Completed	BeiGene	Phase 1	This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
NCT02660034 ↗	The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors	Completed	Myriad Genetic Laboratories, Inc.	Phase 1	The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors
NCT02660034 ↗	The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors	Completed	BeiGene	Phase 1	The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for BGB-290

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Non-small Cell Lung Cancer	5
Marginal Zone Lymphoma	5
Healthy Volunteers	4
Small Lymphocytic Lymphoma	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Neoplasms	25
Lymphoma	23
Carcinoma	12
Lung Neoplasms	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for BGB-290

Trials by Country

Map
Table

Trials by Country for
Location	Trials
China	536
United States	296
Australia	131
France	71
Japan	70
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
Texas	24
California	19
Tennessee	17
New York	17
Pennsylvania	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for BGB-290

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	21
Phase 2	39
Phase 1/Phase 2	14
[disabled in preview]	31
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	38
Completed	29
Active, not recruiting	17
[disabled in preview]	19
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BGB-290

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
BeiGene	87
BeiGene USA, Inc.	3
National Cancer Institute (NCI)	3
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Industry	98
Other	24
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Merck

Colorcon

Medtronic

Dow

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.